Introduction
============

The incidence of thyroid carcinoma is the highest among head and neck carcinomas. Differentiated thyroid carcinoma (DTC) accounts for 90% of thyroid cancers, with 20% of patients experiencing disease relapse, which decreases survival rates ([@b1-ol-0-0-4229]). A timely diagnosis of thyroid cancer recurrence is critical. Evaluation of serum thyroglobulin and ^131^I-diagnostic whole-body scanning (dWBS) are the most commonly employed detection techniques. However, 15--20% of patients with abnormal thyroglobulin levels show negative findings on ^131^I-dWBS ([@b2-ol-0-0-4229],[@b3-ol-0-0-4229]). Furthermore, it is difficult to differentiate the recurrence of DTC from cicatricial tissue by computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), or ultrasound ([@b4-ol-0-0-4229]). Subsequently, PET/CT has been introduced in the diagnostics of DTC, since PET/CT shows metabolic activity and anatomical abnormalities, characteristic of the tumour.

Between December 2005 and June 2013, ^18^F-fluorodeoxyglucose (FDG) PET/CT was utilized to diagnose 15 patients with DTC. The results identified ^18^F-FDG PET/CT as a valuable detecting technique for the recurrence or metastasization of DTC.

Materials and methods
=====================

### Patients

Fifteen patients with DTC were admitted to the Department of Nuclear Medicine of the Xuzhou Central Hospital (Xuzhou, China) between December 2005 and June 2013. There were 3 male and 12 female patients, aged 25--58 years, with a median age of 46 years ([Table I](#tI-ol-0-0-4229){ref-type="table"}). The patients were diagnosed with DTC, and underwent total or subtotal thyroidectomy.

The pathological types comprised 14 cases of papillary carcinoma and 1 case of follicular carcinoma. The patients received 1 or several courses of postoperative treatment with ^131^I: 1 patient was treated once, 4 patients were treated twice, 6 patients were treated three times, 2 patients were treated four times, 1 patient was treated six times, and the remaining patient was treated eight times. At the follow up after the treatment, elevated levels of thyroglobulin (\>20 ng/ml) and negative ^131^I-dWBS findings were present in each of these patients. Subsequently, tumour recurrence or metastasization was suspected. The patients underwent PET/CT examination. Patients continued receiving thyroidin pills following surgery, including during PET/CT, to avoid deterioration of the tumour.

### ^18^F-FDG PET/CT imaging

The Philips GXL 16 PET/CT scanning instrument (Philips Medical Systems, Inc., Cleveland, OH, USA) was used. The patients fasted for ≥6 h prior to scanning. Strict blood glucose levels (non-diabetic patients, \<6.1 mmol/l; patients with diabetes, \<8.3 mmol/l) were maintained. The patients were intravenously administered 270--370 MBq of ^18^F-FDG (4.4 MBq/kg). After 60 min and prior to the scanning, the patients were required to empty their bladders.

Collection ranges were from the basilar part to the proximal femur. The 16-slice helical CT scanning parameters were 140 kV, 320 mA, with flat sweeping. Data were analyzed by image fusion following iterative reconstruction, obtaining coronal, sagittal and cross-sectional CT, PET and PET/CT fusion images. The PET/CT images were reviewed independently by two radiologists who calculated a standardized uptake value of radioactive hot lesion. A standardized uptake value of ≥2.5 localized in metastatic regions was considered as indicative of tumour metastasization.

### Diagnostic criteria of tumour recurrence or metastasization

Based on the positive results of PET/CT scanning, the lesions located in the neck underwent surgical excision, and postoperative histopathology was carried out. The patients were monitored for their serum thyroglobulin levels for 1 month. If the lesions were located in the organs where surgical excision was problematic, the status was determined by clinical situation and the follow-up imaging results within 6 months after the initial PET/CT examination.

### Data analysis

The PET/CT images were qualitatively ranked as true positive, false negative, and false positive. Sensitivity and positive predictive value (PPV) for the diagnosis of recurrence and metastasization of DTC were calculated.

### Statistical analysis

The SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data were presented as mean ± standard deviation. The differences were tested using the paired t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

In 14 patients, PET/CT scanning had a sensitivity of 93.33%. The 14 patients were found to have 40 tumour recurrences or metastases, of which 35 were cervical lymph node metastases ([Fig. 1](#f1-ol-0-0-4229){ref-type="fig"}). The tumours were excised and were identified by postoperative pathology as being tumour metastases in 32 cases and as inflammatory changes in 3 cases. Thus, PPV comprised 91.43%. In 1 patient, 5 lumps were located in the lungs and the mediastinum. No biopsy or surgical intervention were conducted in this patient. The lumps increased during the follow up for 6 months, confirming their metastatic nature.

One patient had negative PET/CT findings and developed neck lumps after 6 months of follow up, which were confirmed as tumour metastases.

A total of 13 patients with preoperative serum thyroglobulin levels of 58.53±18.34 ng/ml underwent surgery. Their postoperation serum thyroglobulin levels were 4.67±1.71 ng/ml (p\<0.05 vs. preoperative).

Discussion
==========

Examination of thyroglobulin levels and ^131^I-dWBS following treatment is important for tumour monitoring and the detection of metastasization in DTC ([@b5-ol-0-0-4229]). Elevated thyroglobulin levels indicate recurrence or metastasization, resulting in ^131^I-dWBS scans being able to locate the tumour. When ^131^I-dWBS shows negative findings, B-mode ultrasound, CT, MRI, PET or other imaging techniques are used to localize recurrent or metastatic tumour. The first three methods are mainly used to locate the tumour by anatomical abnormalities, while PET reveals the tumour through metabolic abnormalities ([@b6-ol-0-0-4229]). Each of these techniques has its advantages and limitations. By contrast, PET/CT imaging can simultaneously reveal metabolic status and anatomical location of the lesion, thus combining the advantages of PET and CT ([@b7-ol-0-0-4229]). This technique is useful in difficult diagnoses, such as that for postoperative scars or nodules, which lack typical benign or malignant signs. Malignant tumours consume glucose at 10-fold higher rates than normal or scar tissue, and this feature enables precise differential diagnosis in those cases ([@b8-ol-0-0-4229]). Therefore, combined functional and morphological examination during PET/CT can improve the ability to detect recurrent and metastatic tumours ([@b9-ol-0-0-4229]).

The diagnostic efficiency of ^18^F-FDG PET/CT imaging in the postoperative follow up of patients with DTC depends on patient selection, sample size, thyroglobulin levels, and thyroid-stimulating hormone levels ([@b10-ol-0-0-4229]). Sensitivity and PPV for recurrence and metastasization of DTC range from 66 to 93.3% and from 87.5 to 100%, respectively ([@b11-ol-0-0-4229]--[@b13-ol-0-0-4229]). These values are significantly higher than those achieved by B-mode ultrasound, CT, MRI, or PET alone. In the present study, sensitivity and PPV were 93.33 and 91.43%, respectively, for patients with positive thyroglobulin levels and negative ^131^I-dWBS findings. This is in agreeement with previous findings ([@b14-ol-0-0-4229]--[@b19-ol-0-0-4229]). In such patients, metastatic tumour is more aggressive, which leads to elevation of the sensitivity of ^18^F-FDG PET/CT imaging. However, tumours that uptake iodine do not uptake FDG, therefore, ^18^F-FDG PET/CT cannot fully replace ^131^I-dWBS and should not be recommended for routine screening for recurrent or metastatic DTC.

In conclusion, findings of the present study indicate that ^18^F-FDG PET/CT imaging is an informative technique for the detection of recurrence or metastasization of DTC in patients with positive thyroglobulin levels and negative ^131^I-dWBS.

![Cervical lymph node metastasis revealed by positron emission tomography/computed tomography (PET/CT) scanning. (A) CT imaging shows no significant neck mass. (B) PET imaging shows two lumpy abnormal radioactive concentration shadows on the right side of the neck. (C) PET/CT imaging shows two abnormal fluorodeoxyglucose hypermetabolism areas in the sternocleidomastoid region of the right side of the neck, which were considered lymph node metastases.](ol-11-04-2420-g00){#f1-ol-0-0-4229}

###### 

Demographic and clinical data of 15 study patients.

  Patient, no.   Gender   Age, years   Histological type of the tumour   PET/CT diagnosis                         Surgery/follow-up confirmation   Preoperative thyroglobulin, ng/ml   Postoperative thyroglobulin, ng/m
  -------------- -------- ------------ --------------------------------- ---------------------------------------- -------------------------------- ----------------------------------- -----------------------------------
  1              Female   36           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        53.36                               4.34
  2              Female   45           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        34.51                               2.47
  3              Male     33           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        61.74                               5.02
  4              Female   48           Follicular carcinoma              4 cervical lymph nodes                   4 in neck                        66.85                               5.77
  5              Female   25           Papillary carcinoma               3 cervical lymph nodes                   2 in neck                        56.27                               4.73
  6              Female   58           Papillary carcinoma               4 cervical lymph nodes                   3 in neck                        72.02                               6.08
  7              Male     55           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        42.25                               3.34
  8              Female   29           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        58.13                               4.86
  9              Female   52           Papillary carcinoma               2 cervical lymph nodes                   2 in neck                        49.61                               3.53
  10             Female   40           Papillary carcinoma               1 cervical lymph node                    1 in neck                        26.68                               1.18
  11             Female   50           Papillary carcinoma               5 cervical lymph nodes                   4 in neck                        83.43                               6.71
  12             Female   42           Papillary carcinoma               3 cervical lymph nodes                   3 in neck                        92.62                               7.29
  13             Female   52           Papillary carcinoma               3 cervical lymph nodes                   3 in neck                        63.45                               5.43
  14             Female   49           Papillary carcinoma               3 in the lung and 2 in the mediastinum   3 in lung and 2 in mediastinum   475.03                              --
  15             Male     46           Papillary carcinoma               Negative                                 1 in neck                        46.02                               --

PET, positron emission tomography; CT, computed tomography.
